Other News To Note
Tuesday, April 26, 2011
KemPharm Inc., of North Liberty, Iowa, said that its attention deficit hyperactivity disorder candidate, KP106, will be formulated in an oral film dosage form in collaboration with MonoSol Rx LLC, of Warren, N.J.. MonoSol acquired exclusive manufacturing rights for the drug in exchange for a share of royalties. It will be responsible for the costs of developing the formulation and manufacturing the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.